Page 20 - Pharma Industry

Leading drug makers Sun Pharma, Lupin recall products in US market

According to USFDA, the Mumbai-based drug maker is recalling the affected lot due to "failed moisture limits."

Novartis cuts uneasy 20-year ties to Roche with $20.7-bn voting stake sale

The company is booking a capital gain of about $14 billion on the investment at a time when the cost of acquisitions in pharma have been soaring

Sun Pharma stock expected to keep market lead as firm recovers in US

Stock trading at the highest discount to ten-year valuation averages, as brokerages favour its US specialty portfolio.

DRL steps up Sputnik V supplies with second dose from Panacea Biotec

Hospital industry sources claim they want assurance on shelf life of imported vaccines

Drugs and Pharma sectors lead growth in India's exports from SEZs

Led by drugs and pharmaceuticals, India's exports from special economic Zones (SEZs) rose by 41.5 per cent on a year-on-year (YoY) basis to Rs 2.15 lakh crore in Q1FY22

Abbott introduces single-dose formulation of carbetocin in India

Drug major Abbott on Tuesday said it has launched room-temperature-stable, single-dose formulation of carbetocin in India to help in the prevention of postpartum haemorrhage (PPH)

Pharma industry to surpass $60 bn by FY24 from $45 bn in FY21: Report

The pandemic push will lead to an 11 per cent annual growth for the pharma sector over the next two years and help it surpass USD 60 billion from around USD 45 billion in FY21, according to a report.

3 reasons why pharma's 'underperformer' tag at markets could change soon

Resolution of supply chain issues, defensive buying and index inclusion are triggers

Work on non-Covid vaccines gives pharma firms an injection of hope

Approach drug regulator, seeking permission to conduct clinical trials

Mandaviya urges pharma industry to increase share of generic drugs in India

Union Health Minister Mansukh Mandaviya on Thursday urged the pharma industry to consider domestic manufacturing of medicines which are soon going to be off patent under Atmanirbhar Bharat

Back to old normal: Pharma industry returns to pre-pandemic growth level

In this first instalment of a four-part series on how some of the defining numbers in key sectors are springing back to the pre-pandemic level, Sohini Das looks at India's pharmaceutical sector

South Korea's bio pharmaceutical exports ranks 7th in world amid Covid-19

Korea's bio pharmaceutical exports rose from 9th to 7th in the world last year

Small contract manufacturers wait to take a shot at Covid vaccines

A host of lesser-known vaccine makers are eyeing contract manufacturing opportunities for global and domestic majors

NPPA allows 50% price hike for ibuprofen, ranitidine, carbamazepine

These are scheduled drugs (or ones that are under price control) and low priced

Sustainable pricing

Govt and vaccine makers should be transparent

Spike in counterfeiting of PPE kits, sanitisers during Covid-19: Report

The COVID-19 lockdown witnessed a sharp spike in counterfeiting incidents in pharmaceutical products, especially PPE kits and sanitisers, as per a report by industry body ASPA. Counterfeiting incidents in India have risen "rapidly in the last few years, with a 20 per cent growth from January 2018 to December 2020, the Authentication Solution Providers' Association (ASPA) said. The top five sectors which have been most affected by counterfeiting are -- alcohol, tobacco, FMCG packaged goods, currency and pharmaceuticals. They together constitute more than 84 per cent of the total counterfeiting incidents reported. Within the last month, there have been a number of cases reported of fake COVID-19 medication. "Counterfeiters are taking advantage of the high demand for medicines, health supplements, safety products, hygiene products and other essentials created due to the COVID crisis and contaminating the market by selling fake and sub-standard products," said the report, titled 'The .

Covid-19 vaccine manufacturers, private hospitals face revenue loss

Back-of-the-envelope calculations show that Serum Institute of India (SII) will lose revenues worth Rs 26.25 crore a month, while Bharat Biotech would lose to the tune of Rs 45 crore a month

After 7,700% surge in stock, Orchid Pharma to face reality check

New owners have to divest part of their stake of about 98 per cent in the firm, which re-listed in Mumbai in early November after emerging from bankruptcy

Powerful lobbying in US against India's Covid vaccine IP waiver push

While big pharma has vehemently opposed India's move on compulsory licensing, even non-pharma influencers such as Bill Gates are against sharing vaccine technology without patenting

Govt gives approval to four firms under PLI scheme for bulk drugs

The government has given approval to four waitlisted firms under the Production Linked Incentive (PLI) scheme for domestic manufacturing of bulk drugs, an official statement said on Monday. The Department of Pharmaceuticals had launched the PLI scheme for promotion of domestic manufacturing of critical bulk drugs -- Key Starting Materials (KSMs)/ Drug Intermediates and Active Pharmaceutical Ingredients (APIs). It envisages setting up greenfield plants in four different target segments with a total outlay of Rs 6,940 crore for the period 2020-21 to 2029-30. All the 215 applications received for the 36 products spread across the four target segments were considered and appraised and selected participants duly informed, the Ministry of Chemicals and Fertilizers said. Now, four waitlisted applicants who are otherwise eligible have been approved against slots vacated by withdrawal by companies which had earlier been granted approvals, the ministry said. The companies which have been gi